HealthDay.com
Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis
In a recent study, significantly more patients receiving the combination therapy met primary end point of reduction in spleen volume of ≥35 percent from baseline
Study Looks at Recovery Potential in Comatose Patients Who Died After Halting Life-Sustaining Therapy
Most patients who died after withdrawal of life-sustaining therapy were considered to have recovery potential of at least 1 percent
Longer PSA Monitoring in Patients With Persistent PSA May Reduce Overtreatment
Authors say PSA level should be assessed for at least three months after radical prostatectomy for prostate cancer to accurately document persistent PSA
Sensorized T-Shirt Enables Early Discharge After Oncological Urology Surgery
90 percent of patients satisfied with remote patient monitoring
Funding Reductions Could Reverse Progress in HIV Response
Greatest effects expected in countries with higher percentage of international funding, with increasing incidence of HIV in key populations
Tuberculosis on the Rise Again in the United States
Preliminary data show 2024 rates were highest seen in more than 12 years
2009 to 2019 Saw Increase in Avoidable Mortality in United States
Decrease in avoidable mortality seen in most comparator countries from European Union and OECD
Trump Administration Ends Dozens of LGBTQ Health Grants
Federal Government Pulls Back $11.4 Billion in COVID Health Funds
Coverage for Routine Childhood Vaccines Remains Below Prepandemic Levels
Vaccine series completion for rotavirus, DTaP, PCV at 12 months was highest in January 2020 and remained lower in October 2023
